Clinical benefits of TNF‐α inhibitors in Chinese adult patients with NLRP3‐associated autoinflammatory disease

Nucleotide‐binding oligomerization domain‐like receptor family, pyrin domain containing 3 (NLRP3)‐associated autoinflammatory disease (NLRP3‐AID) is a rare, heterogeneous disease entity associated with mutations in NLRP3. Biologic therapy for NLRP3‐AID yields diverse results.

[1]  R. Manna,et al.  Current Therapeutic Options for the Main Monogenic Autoinflammatory Diseases and PFAPA Syndrome: Evidence-Based Approach and Proposal of a Practical Guide , 2020, Frontiers in Immunology.

[2]  O. Karadag,et al.  Management of Behcet's syndrome. , 2020, Rheumatology.

[3]  Jing Yang,et al.  USP15 potentiates NF-κB activation by differentially stabilizing TAB2 and TAB3. , 2020, The FEBS journal.

[4]  A. Renieri,et al.  Hints for Genetic and Clinical Differentiation of Adult-Onset Monogenic Autoinflammatory Diseases , 2019, Mediators of inflammation.

[5]  Wen Zhang,et al.  Phenotypes and genotypes of Chinese adult patients with systemic autoinflammatory diseases. , 2019, Seminars in arthritis and rheumatism.

[6]  J. Ting,et al.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.

[7]  G. Konstantopoulou,et al.  Biologics in SAPHO syndrome: A systematic review. , 2019, Seminars in arthritis and rheumatism.

[8]  I. Meyts,et al.  Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment , 2018, Journal of Clinical Immunology.

[9]  I. Touitou,et al.  ‘A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease’ , 2018, Annals of the rheumatic diseases.

[10]  L. Joosten,et al.  OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation , 2018, Proceedings of the National Academy of Sciences.

[11]  D. Kastner,et al.  A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease , 2018, Annals of the rheumatic diseases.

[12]  A. Wree,et al.  TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies , 2017, The Journal of clinical investigation.

[13]  R. Goldbach-Mansky,et al.  Brief Report: Clinical and Molecular Phenotypes of Low‐Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges , 2017, Arthritis & rheumatology.

[14]  M. Shen,et al.  Muckle-Wells syndrome in Chinese patients: a single center case series , 2017, Clinical Rheumatology.

[15]  G. Núñez,et al.  Mechanism and Regulation of NLRP3 Inflammasome Activation. , 2016, Trends in biochemical sciences.

[16]  S. Ozen,et al.  Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS) , 2016, Annals of the rheumatic diseases.

[17]  N. Blank,et al.  Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. , 2016, Rheumatology.

[18]  I. Koné-Paut,et al.  Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome , 2015, Expert review of clinical immunology.

[19]  J. Kuemmerle-Deschner.  CAPS — pathogenesis, presentation and treatment of an autoinflammatory disease , 2015, Seminars in Immunopathology.

[20]  S. Özen,et al.  Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review , 2012, Annals of the rheumatic diseases.

[21]  C. Wouters,et al.  An International registry on Autoinflammatory diseases: the Eurofever experience , 2012, Annals of the rheumatic diseases.

[22]  A. Fabre,et al.  Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France , 2010, Annals of the rheumatic diseases.

[23]  A. Martini,et al.  Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. , 2010, The Journal of pediatrics.

[24]  P. Hawkins,et al.  Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.

[25]  W. Dixon,et al.  Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) , 2009, Annals of the rheumatic diseases.

[26]  G. Núñez,et al.  Cutting Edge: TNF-α Mediates Sensitization to ATP and Silica via the NLRP3 Inflammasome in the Absence of Microbial Stimulation1 , 2009, The Journal of Immunology.

[27]  G. Valesini,et al.  Biological and clinical effects of anti-TNFalpha treatment. , 2007, Autoimmunity reviews.

[28]  Takeo Tanaka,et al.  A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents. , 2006, Arthritis and rheumatism.

[29]  H. Takada,et al.  Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase III pivotal study in Japanese patients. , 2017, Clinical and experimental rheumatology.

[30]  S. Al Jumaah,et al.  A retrospective review of autoinflammatory diseases in Saudi children at a rheumatology clinic , 2012, Annals of Saudi medicine.